EMA/PE/0000230006
Submitted by Anonymous (not verified) on 4 June 2026 - 9:38
EMA/PE/0000230006
EMA/PE/0000229841
Submitted by Anonymous (not verified) on 4 June 2026 - 9:35
EMA/PE/0000229841
EMA/PE/0000227611
Submitted by Anonymous (not verified) on 4 June 2026 - 9:28
EMA/PE/0000227611
EMA/PE/0000183637
Submitted by Anonymous (not verified) on 4 June 2026 - 9:13
EMA/PE/0000183637
EMA/PE/0000232755
Submitted by Anonymous (not verified) on 4 June 2026 - 9:00
EMA/PE/0000232755
PDCO minutes of the 21-24 April 2026 meeting
Submitted by Anonymous (not verified) on 3 June 2026 - 16:31
PDCO minutes of the 21-24 April 2026 meeting
EMA/PE/0000232765
Submitted by Anonymous (not verified) on 3 June 2026 - 16:15
EMA/PE/0000232765
PSUSA/00010508/202509
Submitted by Anonymous (not verified) on 3 June 2026 - 16:00
PSUSA/00010508/202509
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 3 June 2026 - 15:52
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 23, Status: Authorised
Submitted by Anonymous (not verified) on 3 June 2026 - 15:45
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 23, Status: Authorised